Traditional Chinese Herbs in the Management of Type 2 Diabetes
While modern medicine continues to evolve, many people in China turn to time-honored herbal formulas to manage type 2 diabetes. The China SFDA (now known as NMPA) has approved over 30 antidiabetic herbal formulations, reflecting a deep integration of traditional knowledge into contemporary care.
Among the most frequently prescribed herbs, Membranous Milkvetch Root (Huang Qi) stands out for its reputed ability to strengthen qi and support metabolic function. Paired often with Rehmannia Root (Di Huang), known for nourishing yin and balancing blood sugar, these herbs form the backbone of many therapeutic blends.
Other key botanicals include Mongolian Snakegourd Root (Tian Hua Fen), used for clearing heat and promoting fluid production, and Ginseng (Ren Shen), long praised for enhancing vitality and insulin sensitivity. Kudzuvine Root (Ge Gen) is another staple, valued for improving circulation and glucose uptake.
The inclusion of Chinese Magnoliavine Fruit (Wu Wei Zi) and Dwarf Lilyturf Tuber (Mai Dong) points to a holistic approach—targeting not just blood sugar, but also the body’s overall resilience. Common Anemarrhena Rhizome (Zhi Mu) adds a cooling effect, often used when symptoms like thirst and irritability arise. Meanwhile, Barbary Wolfberry Fruit (Gou Qi Zi), better known as goji berry, supports liver and kidney health, often compromised in long-term diabetes.
Interestingly, India Bread—likely a reference to Fu Ling (Poria mushroom)—is also common, though its name may stem from a historic misattribution. Used for draining dampness and strengthening the spleen, it aligns with traditional concepts of metabolic imbalance.
These herbs are rarely used alone. Instead, they’re combined in complex formulas tailored to individual patterns of disharmony—an approach that underscores the personalized nature of traditional Chinese medicine. While research continues, their enduring use suggests a meaningful role in supporting long-term diabetes care.
Comments
No comments yet. Be the first to react.